Efficacy and safety of DPP-4 inhibitors in patients with chronic kidney disease

Efficacy and safety of DPP-4 inhibitors in patients with chronic kidney disease - DPP-4 inhibitors for CKD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018464

Enrollment

100

Registered

2015-07-28

Start date

2011-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic nephropathy and chronic kidney disease

Interventions

sitagliptin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) CKD stage 1-3 2) more than 20 years old and less than 80 tears old 3) HbA1c level more than 7.0% and less than 10% at baseline

Exclusion criteria

Exclusion criteria: 1) CKD stage 4, 5, and 5D 2) less than 20 years old and more than 80 years old 3) Subjects who were treated with steroid 4) Liver dysfunction 5) Subjects who had malignant tumor

Design outcomes

Primary

Measure	Time frame
hemoglobin A1c level, glycated albumin level, postprandial plasma glucose level	—

Countries

Japan

Contacts

Public ContactMasanori Abe

Nihon University School of Medicine Nephrology, Hypertension and Endocrinology

mabe@med.nihon-u.ac.jp03-3972-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026